This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HCA Healthcare Pre-Q3 Earnings: Healthy Buy or a Diagnosis to Wait?
by Zubia Masood
HCA's third-quarter earnings are likely to benefit from improved admissions, capacity additions and payer mix, partially offset by rising operating expenses.
Analyzing Universal Health Pre-Q3 Earnings: Time to Buy the Stock?
by Debasmita Chatterjee
UHS' Q3 results are likely to be driven by rising admissions in acute care hospitals and higher revenue per adjusted patient day in behavioral health hospitals.
Curious about Universal Health Services (UHS) Q3 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Universal Health Services (UHS) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
HCA Healthcare (HCA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
HCA (HCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Universal Health Services (UHS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Universal Health Services (UHS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Community Health Teams Up With Denim to Scale Conversational AI
by Zacks Equity Research
With this move, CYH intends to streamline agent workload, which can result in more savings for the company.
Does Universal Health's Low P/E Ratio Signal a Suitable Entry Point?
by Debasmita Chatterjee
UHS rides on increased patient volumes. It can effectively cater to its patients through its extensive treatment network.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
by Zacks Equity Research
RVTY's continued focus on innovations and a strong product portfolio raise optimism about the stock.
Here's Why You Should Add Masimo Stock to Your Portfolio Now
by Zacks Equity Research
MASI's R&D activities raise optimism about the stock.
Reasons to Retain Cardinal Health Stock in Your Portfolio Now
by Zacks Equity Research
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Is Universal Health Services (UHS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Universal Health Services (UHS) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise
by Zacks Equity Research
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.
Reasons to Add Baxter International Stock to Your Portfolio Now
by Zacks Equity Research
BAX's robust growth across all regions, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Here's Why You Should Retain Merit Medical Stock in Your Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Reasons to Add Avanos Medical Stock in Your Portfolio Now
by Zacks Equity Research
AVNS's strong product line and focus on R&D raise optimism about the stock.
Ensign Expands Presence in Nebraska With Two Acquisitions
by Zacks Equity Research
ENSG's acquisitions in Nebraska are expected to strengthen its portfolio in the region, leading to improved skilled services revenues in the future.
Brookdale Bets Big With $610M Acquisitions Amid Debt Refinancing
by Zacks Equity Research
These acquisitions will add 2,789 units to BKD's owned portfolio and enable it to increase its owned units to 66% of its total units.
FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives
by Zacks Equity Research
Fresenius Medical Care's diversified portfolio helps to fight competition and maintain market leadership.
Stryker Stock Gains 18.6% YTD: What's Driving its Share Price?
by Zacks Equity Research
Styker's flagship, Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Reasons to Retain GE HealthCare Stock in Your Portfolio Now
by Zacks Equity Research
GEHC's continued focus on innovations, acquisitions and partnerships raise optimism about the stock.
SYK Stock May Gain From Completion of Vertos Medical Acquisition
by Zacks Equity Research
Stryker completes the acquisition of Vertos Medical to expand its interventional pain management solutions.
Can Tenet Healthcare's $910M Divestment in Alabama Cure its Debt Woes?
by Zacks Equity Research
More such divestments can be expected from THC in the coming days, which will likely fuel the company's de-leveraging initiatives.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH